메뉴 건너뛰기




Volumn 2, Issue 1, 2008, Pages 21-28

Targeting HER 1 and 2 in breast cancer with lapatinib

Author keywords

EGFR; HER1; HER2; HER3; Lapatinib

Indexed keywords


EID: 77949442039     PISSN: 19705557     EISSN: 19705565     Source Type: Journal    
DOI: 10.1007/s12156-008-0052-6     Document Type: Review
Times cited : (1)

References (61)
  • 2
    • 37049183697 scopus 로고
    • Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
    • Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182 (Pubitemid 17231334)
    • (1987) Science , vol.235 , Issue.4785 , pp. 177-182
    • Slamon, D.J.1    Clark, G.M.2    Wong, S.G.3
  • 6
    • 1242273590 scopus 로고    scopus 로고
    • ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016
    • DOI 10.1038/sj.onc.1207166
    • Xia W, Liu L-H, Ho P, Spector NL (2004) Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW72016. Oncogene 23: 646-653 (Pubitemid 38241266)
    • (2004) Oncogene , vol.23 , Issue.3 , pp. 646-653
    • Xia, W.1    Liu, L.-H.2    Ho, P.3    Spector, N.L.4
  • 8
    • 0034644539 scopus 로고    scopus 로고
    • Cell signaling by receptor tyrosine kinases
    • Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103:211-225
    • (2000) Cell , vol.103 , pp. 211-225
    • Schlessinger, J.1
  • 10
    • 0033542381 scopus 로고    scopus 로고
    • Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation
    • DOI 10.1038/sj.onc.1202698
    • Jones FE, Stern DF (1999) Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation. Oncogene 18: 3481-3490 (Pubitemid 29317343)
    • (1999) Oncogene , vol.18 , Issue.23 , pp. 3481-3490
    • Jones, F.E.1    Stern, D.F.2
  • 11
    • 0033523775 scopus 로고    scopus 로고
    • ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation
    • DOI 10.1083/jcb.147.1.77
    • Jones FE, Welte T, Fu XY, Stern DF (1999) ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation. J Cell Biol 147:77-87 (Pubitemid 30211798)
    • (1999) Journal of Cell Biology , vol.147 , Issue.1 , pp. 77-87
    • Jones, F.E.1    Welte, T.2    Fu, X.-Y.3    Stern, D.F.4
  • 13
    • 0031730476 scopus 로고    scopus 로고
    • Expression of c-erbB3 protein in primary breast carcinomas
    • Naidu R, Yadav M, Nair S, Kutty MK (1998) Expression of cerbB3 protein in primary breast carcinomas. Br J Cancer 78: 1385-1390 (Pubitemid 28495255)
    • (1998) British Journal of Cancer , vol.78 , Issue.10 , pp. 1385-1390
    • Naidu, R.1    Yadav, M.2    Nair, S.3    Kutty, M.K.4
  • 14
    • 0024355092 scopus 로고
    • Autocrine interaction between TGF and the EGF-receptor: Quantitative requirements for induction of the malignant phenotype
    • Di Marco E, Pierce JH, Fleming TP et al (1989) Autocrine interaction between TGF alpha and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. Oncogene 4:831-838 (Pubitemid 19176969)
    • (1989) Oncogene , vol.4 , Issue.7 , pp. 831-838
    • Di Marco, E.1    Pierce, J.H.2    Fleming, T.P.3    Kraus, M.H.4    Molloy, C.J.5    Aaronson, S.A.6    Di Fiore, P.P.7
  • 15
    • 0029665946 scopus 로고    scopus 로고
    • C-erbB3 in human breast carcinoma: Expression and relation to prognosis and established prognostic indicators
    • Travis A, Pinder SE, Robertson JF et al (1996) C-erbB3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer 74:229-233
    • (1996) Br J Cancer , vol.74 , pp. 229-233
    • Travis, A.1    Pinder, S.E.2    Robertson, J.F.3
  • 16
  • 24
    • 2942592008 scopus 로고    scopus 로고
    • Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGFR/ErbB-2 inhibitor lapatinib
    • Burris HA III (2004) Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 9(suppl 3):10-15
    • (2004) Oncologist , vol.9 , Issue.SUPPL. 3 , pp. 10-15
    • Burris Iii, H.A.1
  • 25
    • 0029912203 scopus 로고    scopus 로고
    • All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired
    • DOI 10.1074/jbc.271.9.5251
    • Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G (1996) All erbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 271: 5251-5257 (Pubitemid 26075021)
    • (1996) Journal of Biological Chemistry , vol.271 , Issue.9 , pp. 5251-5257
    • Baulida, J.1    Kraus, M.H.2    Alimandi, M.3    Di Fiore, P.P.4    Carpenter, G.5
  • 27
    • 34948909630 scopus 로고    scopus 로고
    • Lapatinib (L) plus capecitabine (C) in HER2+advanced breast cancer (ABC): Genomic and updated efficacy data
    • abstr 1035
    • Geyer CE, Martin A, Newstat B et al (2007) Lapatinib (L) plus capecitabine (C) in HER2+advanced breast cancer (ABC): genomic and updated efficacy data. Proc Am Soc Clin Oncol 25(18S), abstr 1035
    • (2007) Proc Am Soc Clin Oncol , vol.25 , Issue.18 S
    • Geyer, C.E.1    Martin, A.2    Newstat, B.3
  • 28
    • 56549113680 scopus 로고    scopus 로고
    • A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses
    • Jan 11 [Epub ahead of print]
    • Cameron D, Casey M, Press M et al (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat Jan 11 [Epub ahead of print]
    • (2008) Breast Cancer Res Treat
    • Cameron, D.1    Casey, M.2    Press, M.3
  • 29
    • 34047248199 scopus 로고    scopus 로고
    • Lapatinib plus capecitabine in breast cancer
    • Sonpavde G (2007) Lapatinib plus capecitabine in breast cancer. N Engl J Med 356:1471-1472
    • (2007) N Engl J Med , vol.356 , pp. 1471-1472
    • Sonpavde, G.1
  • 30
    • 34147096113 scopus 로고    scopus 로고
    • Lapatinib plus capecitabine in breast cancer
    • Geyer CE, Forster J, Cameron MD (2007) Lapatinib plus capecitabine in breast cancer. N Engl J Med 356:1471-1472
    • (2007) N Engl J Med , vol.356 , pp. 1471-1472
    • Geyer, C.E.1    Forster, J.2    Cameron, M.D.3
  • 31
    • 30544440228 scopus 로고    scopus 로고
    • Interim results of a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with FISH-amplified advanced or metastatic breast cancer
    • Stein SH, Gomez HL, Chavez MA et al (2005) Interim results of a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with FISH-amplified advanced or metastatic breast cancer. Eur J Cancer 3(suppl):78
    • (2005) Eur J Cancer , vol.3 , Issue.SUPPL. , pp. 78
    • Stein, S.H.1    Gomez, H.L.2    Chavez, M.A.3
  • 33
    • 34250655315 scopus 로고    scopus 로고
    • Cardiac safety experience in 3127 patients treated with lapatinib
    • Perez EA, Byrne JA, Hammond IW et al (2006) Cardiac safety experience in 3127 patients treated with lapatinib. Ann Oncol 17(suppl 9):1420
    • (2006) Ann Oncol , vol.17 , Issue.SUPPL. 9 , pp. 1420
    • Perez, E.A.1    Byrne, J.A.2    Hammond, I.W.3
  • 34
    • 0033838655 scopus 로고    scopus 로고
    • Incidence and epidemiology of heart failure
    • Kannel WB (2000) Incidence and epidemiology of heart failure. Heart Fail Rev 5:167-173
    • (2000) Heart Fail Rev , vol.5 , pp. 167-173
    • Kannel, W.B.1
  • 35
    • 33645792831 scopus 로고    scopus 로고
    • Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy
    • Montemurro F, Donadio M, Clavarezza M et al (2006) Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 11: 318-324
    • (2006) Oncologist , vol.11 , pp. 318-324
    • Montemurro, F.1    Donadio, M.2    Clavarezza, M.3
  • 36
    • 34948911758 scopus 로고    scopus 로고
    • Preclinical study of continuous administration trastuzumab as combination therapy after disease progresses with trastuzumab monotherapy
    • abstr 5062
    • Fujimoto-Ouchi K, Sekiguchi F, More I (2005) Preclinical study of continuous administration trastuzumab as combination therapy after disease progresses with trastuzumab monotherapy. Proc Am Assoc Cancer Res 46, abstr 5062
    • (2005) Proc Am Assoc Cancer Res , vol.46
    • Fujimoto-Ouchi, K.1    Sekiguchi, F.2    More, I.3
  • 39
    • 33645538673 scopus 로고    scopus 로고
    • Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study
    • Bartsch R, Wenzel C, Hussian D et al (2006) Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. BMC Cancer 6:63-68
    • (2006) BMC Cancer , vol.6 , pp. 63-68
    • Bartsch, R.1    Wenzel, C.2    Hussian, D.3
  • 42
    • 12744279331 scopus 로고    scopus 로고
    • Increased risk of brain metastasis in patients with HER-2/neupositive breast carcinoma
    • Altaha R, Crowell E, Hobbs G, Higa G, Abraham J (2005) Increased risk of brain metastasis in patients with HER-2/neupositive breast carcinoma. Cancer 103:442-443
    • (2005) Cancer , vol.103 , pp. 442-443
    • Altaha, R.1    Crowell, E.2    Hobbs, G.3    Higa, G.4    Abraham, J.5
  • 43
    • 34948902249 scopus 로고    scopus 로고
    • Brain metastases (BM) in patients treated with trastuzumab for HER overexpressing metastatic breast cancer (MBC): Incidence and survival
    • abstr 1568
    • Stemmler J, Kahlert S, Siekiera Wet al (2005) Brain metastases (BM) in patients treated with trastuzumab for HER overexpressing metastatic breast cancer (MBC): incidence and survival. J Clin Oncol 23(16 suppl), abstr 1568
    • (2005) J Clin Oncol , vol.23 , Issue.16 SUPPL.
    • Stemmler, J.1    Kahlert, S.2    Siekiera, W.3
  • 44
    • 33746512271 scopus 로고    scopus 로고
    • Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer
    • abstr 503
    • Lin NU, Carey LA, Liu MC et al (2006) Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. J Clin Oncol 24(18S Part I), abstr 503
    • (2006) J Clin Oncol , vol.24 , Issue.18 PART I
    • Lin, N.U.1    Carey, L.A.2    Liu, M.C.3
  • 45
    • 34848899905 scopus 로고    scopus 로고
    • EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT)
    • abstr 1012
    • Lin NU, Dieras V, Paul D et al (2007) EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). Proc Am Soc Clin Oncol 25(18S), abstr 1012
    • (2007) Proc Am Soc Clin Oncol , vol.25 , Issue.18 S
    • Lin, N.U.1    Dieras, V.2    Paul, D.3
  • 46
    • 0029053716 scopus 로고
    • Cooperative signaling of erbB3 and erbB2 in neoplastic transformation and human mammary carcinomas
    • Alimandi M, Romano A, Curia MC et al (1995) Cooperative signaling of erbB3 and erbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10:1813-1821
    • (1995) Oncogene , vol.10 , pp. 1813-1821
    • Alimandi, M.1    Romano, A.2    Curia, M.C.3
  • 47
    • 0024395587 scopus 로고
    • Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts
    • DOI 10.1016/0092-8674(89)90843-X
    • Kokai Y, Myers JN, Wada T et al (1989) Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 58:287-292 (Pubitemid 19191411)
    • (1989) Cell , vol.58 , Issue.2 , pp. 287-292
    • Kokai, Y.1    Myers, J.N.2    Wada, T.3    Brown, V.I.4    LeVea, C.M.5    Davis, J.G.6    Dobashi, K.7    Greene, M.I.8
  • 48
    • 0023733226 scopus 로고
    • Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene
    • Segatto O, King CR, Pierce JH, DiFiore PP, Aaronson SA (1988) Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell Biol 8:5570-5574
    • (1988) Mol Cell Biol , vol.8 , pp. 5570-5574
    • Segatto, O.1    King, C.R.2    Pierce, J.H.3    Difiore, P.P.4    Aaronson, S.A.5
  • 51
    • 0035893560 scopus 로고    scopus 로고
    • Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo
    • Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL (2001) Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61:8887-8895 (Pubitemid 34013905)
    • (2001) Cancer Research , vol.61 , Issue.24 , pp. 8887-8895
    • Moulder, S.L.1    Yakes, F.M.2    Muthuswamy, S.K.3    Bianco, R.4    Simpson, J.F.5    Arteaga, C.L.6
  • 52
    • 20144377465 scopus 로고    scopus 로고
    • HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells
    • DOI 10.1158/0008-5472.CAN-04-2748
    • Hirata A, Hosoi F, Miyagawa M et al (2005) HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res 65:4253-4260 (Pubitemid 40775664)
    • (2005) Cancer Research , vol.65 , Issue.10 , pp. 4253-4260
    • Hirata, A.1    Hosoi, F.2    Miyagawa, M.3    Ueda, S.-I.4    Naito, S.5    Fujii, T.6    Kuwano, M.7    Ono, M.8
  • 53
    • 0037388251 scopus 로고    scopus 로고
    • ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells
    • Anido J, Matar P, Albanell et al (2003) ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER-overexpressing breast cancer cells. Clin Cancer Res 9: 1274-1283 (Pubitemid 36418377)
    • (2003) Clinical Cancer Research , vol.9 , Issue.4 , pp. 1274-1283
    • Anido, J.1    Matar, P.2    Albanell, J.3    Guzman, M.4    Rojo, F.5    Arribas, J.6    Averbuch, S.7    Baselga, J.8
  • 54
    • 0031010495 scopus 로고    scopus 로고
    • Secondary dimerization between members of the epidermal growth factor receptor family
    • DOI 10.1074/jbc.272.18.12052
    • Gamett DC, Pearson G, Cerione RA, Friedberg I (1997) Secondary dimerization between members of the epidermal growth factor receptor family. J Biol Chem 272:12052-12056 (Pubitemid 27202783)
    • (1997) Journal of Biological Chemistry , vol.272 , Issue.18 , pp. 12052-12056
    • Gamett, D.C.1    Pearson, G.2    Cerione, R.A.3    Friedberg, I.4
  • 55
    • 0028968949 scopus 로고
    • Tyrosine kinase inhibition: An approach to drug development
    • Levitzki A, Gazit A (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267:1782-1788
    • (1995) Science , vol.267 , pp. 1782-1788
    • Levitzki, A.1    Gazit, A.2
  • 56
    • 23944464495 scopus 로고    scopus 로고
    • Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer
    • Baselga J, Albanell J, Ruiz A et al (2005) Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 23:5323-5233
    • (2005) J Clin Oncol , vol.23 , pp. 5323-5233
    • Baselga, J.1    Albanell, J.2    Ruiz, A.3
  • 58
    • 0036848757 scopus 로고    scopus 로고
    • Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer
    • Tsutsui S, Kataoka A, Ohno S, Murakami S, Kinoshita J, Hachitanda Y (2002) Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin Cancer Res 8:3454-3460 (Pubitemid 35340721)
    • (2002) Clinical Cancer Research , vol.8 , Issue.11 , pp. 3454-3460
    • Tsutsui, S.1    Kataoka, A.2    Ohno, S.3    Murakami, S.4    Kinoshita, J.5    Hachitanda, Y.6
  • 61
    • 33644626501 scopus 로고    scopus 로고
    • ECOG E1100: A phase II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpress HER2/neu (erbB-2)
    • ECOG E1100: a phase II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpress HER2/neu (erbB-2). Clin Adv Hematol Oncol 2003;1:237
    • (2003) Clin Adv Hematol Oncol , vol.1 , pp. 237


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.